Importer of Controlled Substances Registration: Almac Clinical Services, Inc. (ACSI), 44866-44867 [2014-18279]

Download as PDF tkelley on DSK3SPTVN1PROD with NOTICES 44866 Federal Register / Vol. 79, No. 148 / Friday, August 1, 2014 / Notices General information concerning the Commission may also be obtained by accessing its Internet server at United States International Trade Commission (USITC) at USITC.2 The public record for this investigation may be viewed on the Commission’s Electronic Document Information System (EDIS) at EDIS.3 Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal on (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission has received a complaint and a submission pursuant to section 210.8(b) of the Commission’s Rules of Practice and Procedure filed on behalf of Valeo North America, Inc. and Delmex de Juarez S. de R.L. de C.V. on July 25, 2014. The complaint alleges violations of section 337 of the Tariff Act of 1930 (19 U.S.C. 1337) in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain windshield wipers and components thereof. The complaint names as respondents Federal-Mogul Corp. of Southfield, MI; Federal-Mogul Vehicle Component Solutions, Inc. of Southfield, MI and Federal-Mogul S.A. of Belgium. The complainant requests that the Commission issue a permanent limited exclusion order and permanent cease and desist orders. Proposed respondents, other interested parties, and members of the public are invited to file comments, not to exceed five (5) pages in length, inclusive of attachments, on any public interest issues raised by the complaint or section 210.8(b) filing. Comments should address whether issuance of the relief specifically requested by the complainant in this investigation would affect the public health and welfare in the United States, competitive conditions in the United States economy, the production of like or directly competitive articles in the United States, or United States consumers. In particular, the Commission is interested in comments that: (i) Explain how the articles potentially subject to the requested remedial orders are used in the United States; (ii) identify any public health, safety, or welfare concerns in the United States relating to the requested remedial orders; 2 United States International Trade Commission (USITC): https://edis.usitc.gov. 3 Electronic Document Information System (EDIS): https://edis.usitc.gov. VerDate Mar<15>2010 22:09 Jul 31, 2014 Jkt 232001 (iii) identify like or directly competitive articles that complainant, its licensees, or third parties make in the United States which could replace the subject articles if they were to be excluded; (iv) indicate whether complainant, complainant’s licensees, and/or third party suppliers have the capacity to replace the volume of articles potentially subject to the requested exclusion order and/or a cease and desist order within a commercially reasonable time; and (v) explain how the requested remedial orders would impact United States consumers. Written submissions must be filed no later than by close of business, eight calendar days after the date of publication of this notice in the Federal Register. There will be further opportunities for comment on the public interest after the issuance of any final initial determination in this investigation. Persons filing written submissions must file the original document electronically on or before the deadlines stated above and submit 8 true paper copies to the Office of the Secretary by noon the next day pursuant to section 210.4(f) of the Commission’s Rules of Practice and Procedure (19 CFR 210.4(f)). Submissions should refer to the docket number (‘‘Docket No. 3025’’) in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, Electronic Filing Procedures 4). Persons with questions regarding filing should contact the Secretary (202–205–2000). Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All nonconfidential written submissions will be available for public inspection at the Office of the Secretary and on EDIS.5 This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and of sections 201.10 and 210.8(c) of the Commission’s Rules of Practice and Procedure (19 CFR 201.10, 210.8(c)). By order of the Commission. Issued: July 28, 2014. Lisa R. Barton, Secretary to the Commission. 4 Handbook for Electronic Filing Procedures: https://www.usitc.gov/secretary/fed_reg_notices/ rules/handbook_on_electronic_filing.pdf. 5 Electronic Document Information System (EDIS): https://edis.usitc.gov. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Tapentadol (9780) ........................ Fentanyl (9801) ............................ PO 00000 Frm 00129 Fmt 4703 Sfmt 4703 [FR Doc. 2014–18084 Filed 7–31–14; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Registration: Almac Clinical Services, Inc. (ACSI) ACTION: Notice of registration. Almac Clinical Services, Inc. (ACSI) applied to be registered as an importer of certain basic classes of narcotic controlled substances. The Drug Enforcement Administration (DEA) grants Almac Clinical Services, Inc. (ACSI) registration as an importer of those controlled substances. SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and published in the Federal Register on April 28, 2014, 79 FR 23373, Almac Clinical Services, Inc. (ACSI), 25 Fretz Road, Souderton, Pennsylvania 18964, applied to be registered as an importer of certain basic classes of controlled substances. No comments or objections were submitted for this notice. The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of Almac Clinical Services, Inc., (ACSI) to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above-named company is granted registration as an importer of the basic classes of controlled substances listed: SUMMARY: Controlled substance E:\FR\FM\01AUN1.SGM 01AUN1 Schedule II II II II Federal Register / Vol. 79, No. 148 / Friday, August 1, 2014 / Notices The company plans to import small quantities of the listed controlled substances in dosage form to conduct clinical trials. The import of the above listed basic classes of controlled substances is granted only for analytical testing and clinical trials. This authorization does not extend to the import of finished Food and Drug Administration approved or non-approved dosage forms for commercial distribution in the United States. Dated: July 22, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator. [FR Doc. 2014–18279 Filed 7–31–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Comment Request for Information Collection for the Youth Career Connect Grant Program, New Collection Office of the Assistant Secretary for Policy, Department of Labor. ACTION: Notice. AGENCY: The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) [44 U.S.C. 3506(c)(2)(A)]. This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents are properly assessed. Currently, the Department of Labor is soliciting comments concerning the collection of data about Youth Career Connect (YCC) [SGA/DFA PY–13–01] grant program. A copy of the proposed Information Collection Request (ICR) can be obtained by contacting the office listed below in the addressee section of this notice. DATES: Written comments must be submitted to the office listed in the addressee’s section below on or before September 30, 2014. ADDRESSES: Submit written comments to Office of the Assistant Secretary for Policy, 200 Constitution Avenue NW., Room S–2312, Washington, DC 20210, tkelley on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 22:09 Jul 31, 2014 Jkt 232001 Attention: Evan Rosenberg. Telephone number: 202–693–3949 (this is not a toll-free number). Fax: 202–693–3593. Email: ycc@dol.gov. SUPPLEMENTARY INFORMATION: I. Background In applying for the YCC grant program, grantees agreed to submit participant-level data and quarterly aggregate reports for individuals who receive services through YCC programs and their partnerships with entities administering the workforce investment system as established under Section 1169(b) and 117 of the Workforce Investment Act of 1998 (WIA), Local Education Agencies (LEA’s), non-profit organizations with program model experience, education and training providers such as community colleges and other institutions of higher education and employer partners. The reports will include aggregate data on demographic characteristics, types of services received, placements, program outcomes, and follow-up status. Specifically, they will summarize data on participants who received core YCC program services, program enrollment, retention and credential rates, placement services, and other services essential to successful outcomes for YCC program participants. This document requests approval for a new information collection to meet the reporting and recordkeeping requirements of the YCC grant program. Five outcome measures will be used to measure success in the YCC grant programs: Long-Term Measures • Final Program Retention Rate—the percentage of participants who complete the program, of those who enter the program; • High School Diploma Attainment Rate—the percentage of participants who attain a high-school diploma; • Credential Attainment Rate—the percentage of participants who attain an industry-recognized credential in the specified H–1B industry or occupation; • Diploma and Credential Attainment Rate—the percentage of participants who attain a high-school diploma and credential in the specified H–1B industry or occupation; and • Placement Rate—the percentage of participants who are placed in one of the following: Unsubsidized employment, post-secondary education, occupational skills training, or Registered Apprenticeship. (The performance report also will include separate counts of the number of participants who enter unsubsidized employment, enter post-secondary PO 00000 Frm 00130 Fmt 4703 Sfmt 4703 44867 education, enter occupational skills training, and enter a Registered Apprenticeship.) In addition to the five outcome measures described above, grantees will report on a number of leading indicators that serve as predictors of success. These indicators include the following short and long-term measures: Short-Term Measures • Enrollment Rate—the number of participants enrolled in the program compared to the target number of participants identified in the grant application; • Attendance Rate—the rate of school attendance by participants in the program; • Chronic Absence Rate—the percentage of participants who have missed 10 percent of school days for any reason-excused or unexcused—as well as suspensions; • Mentoring Rate—percentage of participants who have matched mentors and participate in formal mentoring; • Yearly Program Retention Rate— percentage of participants who continue in program from one school year to the next; • Work Readiness Indicator—the percentage of participants who are deemed work ready based on an employer evaluation conducted at the end of each internship/work experience (using the DOL-developed work readiness tool found at: https:// wdr.doleta.gov/directives/attach/TEGL/ TEGL07-10a4.pdf); • Internship Placement and Completion Rates—the percentage of program participants who begin an internship and, of those who begin an internship, the percentage who complete; • Post-Secondary Credit Attainment Rate—the percentage of participants who attain post-secondary education credit from courses taken during the program; and • Average Post-Secondary Credit Hours Attained—the average number of post-secondary credits attained per participant while in the program. This information collection maintains a reporting and record-keeping system for a minimum level of information collection that is necessary to comply with Equal Opportunity requirements, to hold YCC grantees appropriately accountable for the Federal funds they receive, allowing the Department to fulfill its oversight and management responsibilities. The information collection for YCC grantee performance reporting includes setting up an online Participant E:\FR\FM\01AUN1.SGM 01AUN1

Agencies

[Federal Register Volume 79, Number 148 (Friday, August 1, 2014)]
[Notices]
[Pages 44866-44867]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-18279]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Registration: Almac Clinical 
Services, Inc. (ACSI)

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: Almac Clinical Services, Inc. (ACSI) applied to be registered 
as an importer of certain basic classes of narcotic controlled 
substances. The Drug Enforcement Administration (DEA) grants Almac 
Clinical Services, Inc. (ACSI) registration as an importer of those 
controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and 
published in the Federal Register on April 28, 2014, 79 FR 23373, Almac 
Clinical Services, Inc. (ACSI), 25 Fretz Road, Souderton, Pennsylvania 
18964, applied to be registered as an importer of certain basic classes 
of controlled substances. No comments or objections were submitted for 
this notice.
    The Drug Enforcement Administration (DEA) has considered the 
factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the 
registration of Almac Clinical Services, Inc., (ACSI) to import the 
basic classes of controlled substances is consistent with the public 
interest and with United States obligations under international 
treaties, conventions, or protocols in effect on May 1, 1971. The DEA 
investigated the company's maintenance of effective controls against 
diversion by inspecting and testing the company's physical security 
systems, verifying the company's compliance with state and local laws, 
and reviewing the company's background and history.
    Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above-named company is granted 
registration as an importer of the basic classes of controlled 
substances listed:

------------------------------------------------------------------------
            Controlled substance                       Schedule
------------------------------------------------------------------------
Oxycodone (9143)...........................  II
Hydromorphone (9150).......................  II
Tapentadol (9780)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------


[[Page 44867]]

    The company plans to import small quantities of the listed 
controlled substances in dosage form to conduct clinical trials.
    The import of the above listed basic classes of controlled 
substances is granted only for analytical testing and clinical trials. 
This authorization does not extend to the import of finished Food and 
Drug Administration approved or non-approved dosage forms for 
commercial distribution in the United States.

    Dated: July 22, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-18279 Filed 7-31-14; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.